3/18
01:23 pm
inkt
MiNK Therapeutics, Inc. (NASDAQ: INKT) had its "buy" rating re-affirmed by analysts at HC Wainwright. They now have a $35.00 price target on the stock.
Medium
Report
MiNK Therapeutics, Inc. (NASDAQ: INKT) had its "buy" rating re-affirmed by analysts at HC Wainwright. They now have a $35.00 price target on the stock.